Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hemofiltration Basic Solution is a sterile, intravenous replacement fluid designed for use in continuous renal replacement therapy (CRRT), specifically hemofiltration. Developed and manufactured by **Shijiazhuang No. 4 Pharmaceutical Co., Ltd.**, this solution serves to replace water and electrolytes lost during the filtration process, effectively substituting for partial kidney function. The formulation is notably potassium-free to facilitate the removal of excess potassium in patients with hyperkalemia, though potassium salts can be added based on individual clinical needs. It is primarily indicated for patients with acute kidney injury (AKI) or other critical renal conditions requiring continuous blood purification.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hemofiltration basic solution.